Latest Conference Articles

May 28th 2020, 1:38am

ESMO Breast Cancer Virtual Meeting

Fabrice André, MD, PhD, discusses strategies to improve outcomes in patients with breast cancer.

May 28th 2020, 1:35am

ESMO Breast Cancer Virtual Meeting

Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

May 27th 2020, 1:48am

ESMO Breast Cancer Virtual Meeting

The PARP inhibitor veliparib increased progression-free survival in women with hormone receptor-positive breast cancer and triple-negative breast cancer who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694).

May 26th 2020, 11:40pm

ESMO Breast Cancer Virtual Meeting

Developing diagnostics to identify the molecular drivers of breast cancer and model the mechanisms of disease progression will be a key priority of the investigative efforts aimed at improving patient outcomes in the field over the next decade.

May 26th 2020, 5:25pm

ESMO Breast Cancer Virtual Meeting

LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.

May 24th 2020, 8:09pm

ESMO Breast Cancer Virtual Meeting

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline.

May 24th 2020, 7:36pm

ESMO Breast Cancer Virtual Meeting

Although little evidence exists with regard to how to best treat patients with breast cancer during the COVID-19 pandemic, guidelines have been issued by organizations like ESMO to assist providers with making those decisions.

May 23rd 2020, 8:10pm

ESMO Breast Cancer Virtual Meeting

Adding ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival in patients with triple-negative breast cancer.

May 23rd 2020, 8:00pm

ESMO Breast Cancer Virtual Meeting

Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.

May 23rd 2020, 8:00pm

ESMO Breast Cancer Virtual Meeting

Rebecca Dent, MD, discusses the findings from the phase 2 LOTUS trial that treated patients with inoperable locally advanced/metastatic triple-negative breast cancer with first-line ipatasertib plus paclitaxel.

May 21st 2020, 3:09pm

ASCO Annual Meeting

We spoke with leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their specialties.

May 21st 2020, 11:16am

ASCO Annual Meeting

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

May 14th 2020, 1:11am

ASCO Annual Meeting

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

May 14th 2020, 1:00am

ASCO Annual Meeting

The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found.

May 14th 2020, 1:00am

ASCO Annual Meeting

The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than one hour away from the patient.

May 13th 2020, 9:00pm

ASCO Annual Meeting

Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.

May 13th 2020, 9:00pm

ASCO Annual Meeting

Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.

May 4th 2020, 4:30pm

PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

Transformative clinical trials of PARP inhibitors have revolutionized the frontline treatment paradigm in advanced ovarian cancer.

May 3rd 2020, 3:47pm

PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.

May 3rd 2020, 12:40am

PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians.